Sensei biotherapeutics announces new preclinical data demonstrating favorable pharmacokinetic and immunologic effects of sns-101, a ph-selective vista-blocking antibody

Boston, mass., aug. 31, 2022 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today reported preliminary preclinical data from mouse and non-human primate studies of sns-101, a monoclonal antibody targeting the immune checkpoint vista (v-domain ig suppressor of t cell activation).
SNSE Ratings Summary
SNSE Quant Ranking